[go: up one dir, main page]

MX2018002263A - Potenciador de atp intracelular. - Google Patents

Potenciador de atp intracelular.

Info

Publication number
MX2018002263A
MX2018002263A MX2018002263A MX2018002263A MX2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A
Authority
MX
Mexico
Prior art keywords
cells
agent
inosine
atp
pharmaceutically acceptable
Prior art date
Application number
MX2018002263A
Other languages
English (en)
Other versions
MX390332B (es
Inventor
Nishino Takeshi
Kamatani Naoyuki
Original Assignee
Stagen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stagen Co Ltd filed Critical Stagen Co Ltd
Publication of MX2018002263A publication Critical patent/MX2018002263A/es
Publication of MX390332B publication Critical patent/MX390332B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un problema a ser resuelto por la presente invención es proporcionar una sustancia que tenga un efecto de aumentar el ATP intracelular y, en términos particulares, un potente potenciador de ATP que supere por mucho el efecto cada vez mayor de inosina o febuxostat por sí solos. Un potenciador de ATP intracelular de origen humano o animal que comprende una combinación de A) y B): A) un inhibidor de xantina oxidasa/xantina deshidrogenasa o una sal farmacéuticamente aceptable del mismo; y B) cualquiera o cualesquiera de los compuestos seleccionados a partir de inosina, ácido inosínico, hipoxantina y sales farmacéuticamente aceptables de los mismos.
MX2018002263A 2015-08-26 2016-08-24 Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. MX390332B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015166372 2015-08-26
PCT/JP2016/074644 WO2017033963A1 (ja) 2015-08-26 2016-08-24 細胞内ａｔｐ増強剤

Publications (2)

Publication Number Publication Date
MX2018002263A true MX2018002263A (es) 2018-03-23
MX390332B MX390332B (es) 2025-03-20

Family

ID=58100417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002263A MX390332B (es) 2015-08-26 2016-08-24 Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular.

Country Status (10)

Country Link
US (1) US10682372B2 (es)
EP (1) EP3342414B1 (es)
JP (2) JP6153281B1 (es)
KR (1) KR102600879B1 (es)
CN (1) CN107921054B (es)
BR (1) BR112018002648B1 (es)
CA (1) CA2995052C (es)
MX (1) MX390332B (es)
RU (1) RU2728722C2 (es)
WO (1) WO2017033963A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3054963B1 (fr) * 2016-08-10 2018-09-14 Assistance Publique-Hopitaux De Paris (Ap-Hp) Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6937134B2 (ja) 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
US20220072022A1 (en) * 2019-01-18 2022-03-10 Stagen Co., Ltd. Anti-aging agent or life-extending agent
US11491175B2 (en) 2019-02-25 2022-11-08 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
JP7333942B2 (ja) 2019-06-07 2023-08-28 株式会社スタージェン 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
CN110441457A (zh) * 2019-08-02 2019-11-12 深圳市绿航星际太空科技研究院 一种检测尿液中同型半胱氨酸的方法
US20240051971A1 (en) * 2020-12-08 2024-02-15 School Juridical Person Higashi-Nippon-Gakuen Intracellular atp enhancer
JPWO2023135827A1 (es) * 2022-01-13 2023-07-20
CN116763751A (zh) * 2023-07-25 2023-09-19 华中药业股份有限公司 一种肌苷片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
JP5110536B2 (ja) 2006-07-19 2012-12-26 学校法人日本医科大学 筋萎縮性側索硬化症治療薬
CA2659511A1 (en) * 2006-08-02 2008-02-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticonvulsive pharmaceutical compositions
ES2513390T3 (es) * 2007-11-27 2014-10-27 Ardea Biosciences, Inc. Nuevos compuestos y composiciones, y métodos de uso
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
CN102106896B (zh) * 2009-12-23 2012-05-30 昆明贝叶傣医药研究所 中药材土千年健在制药中的新应用
WO2012014117A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Improved process for the preparation of febuxostat
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
CN102994537A (zh) * 2012-11-21 2013-03-27 广东肇庆星湖生物科技股份有限公司 一种嘌呤核苷磷酸化酶基因敲除的大肠杆菌Ecoli-SL26的构建方法

Also Published As

Publication number Publication date
JPWO2017033963A1 (ja) 2017-08-24
RU2018110363A3 (es) 2020-01-29
WO2017033963A1 (ja) 2017-03-02
JP6153281B1 (ja) 2017-06-28
BR112018002648A2 (es) 2018-10-02
HK1246165A1 (zh) 2018-09-07
RU2728722C2 (ru) 2020-07-30
EP3342414B1 (en) 2022-04-06
CN107921054B (zh) 2020-12-04
MX390332B (es) 2025-03-20
CA2995052C (en) 2023-08-22
US20180243326A1 (en) 2018-08-30
KR102600879B1 (ko) 2023-11-09
US10682372B2 (en) 2020-06-16
JP2017141308A (ja) 2017-08-17
EP3342414A1 (en) 2018-07-04
CN107921054A (zh) 2018-04-17
CA2995052A1 (en) 2017-03-02
KR20180039164A (ko) 2018-04-17
BR112018002648B1 (pt) 2024-01-09
EP3342414A4 (en) 2019-04-17
RU2018110363A (ru) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2018002263A (es) Potenciador de atp intracelular.
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CO2017004784A2 (es) Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a
SV2016005206A (es) Derivados novedosos de amino pirimidina
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
MX2018016287A (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
CR20130680A (es) Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i
BR112015020466A2 (pt) inibidores de cdc7
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
CL2016000241A1 (es) Formulación de inhibidores de la syk.
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CR20150427A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2 (1h)-ona que tienen actividad agonista del receptor b2 adrenérgico así como actividad antagonista del receptor
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
MX389961B (es) Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
JOP20180127A1 (ar) صيغ صلبة من منشط محلقة غوانيليل قابل للذوبان (sGC)
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
MX2019010595A (es) Derivados de pirrolotriazina como inhibidores de cinasas.
CY1123832T1 (el) Συνθεσεις καταλληλες για τη διατηρηση της φυσιολογικης συνθηκης του δερματος και των μαλλιων και την επαναφορα των αναγεννητικων τους λειτουργιων
AR101252A1 (es) Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
AR090959A1 (es) Analogos de hexadepsipeptidos como compuestos anticancerigenos
EA201691596A1 (ru) Составы гепарина для наружного применения